THERAVANCE BIOPHARMA,INC. (NASDAQ:TBPH) Files An 8-K Results of Operations and Financial Condition

THERAVANCE BIOPHARMA,INC. (NASDAQ:TBPH) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

Story continues below

On May 9, 2017 at 5:00 p.m. ET, Theravance Biopharma, Inc. held a previously announced conference call regarding our financial results for the quarter ended March 31, 2017 and a business update. Attached as Exhibit 99.1 is the script that was used for the conference call. We are furnishing the script on this Form 8-K because certain individuals listening to our conference call had difficultly hearing portions of the conference call due to transmission issues that were outside of our control.

The information in Item 2.02 and in Item 9.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act of 1934”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Script used in the previously announced Theravance Biopharma, Inc. conference call held May 9, 2017



Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.


THERAVANCE BIOPHARMA, INC. (NASDAQ:TBPH) closed its last trading session up +0.59 at 40.65 with 124,234 shares trading hands.

An ad to help with our costs